Effectiveness of switching antipsychotic medications

The American Journal of Psychiatry
Susan M EssockJeffrey A Lieberman

Abstract

Changing antipsychotics is common despite the dearth of information on risks and benefits associated with medication changes. The authors examined phase 1 findings from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study to explore whether it was more advantageous to continue taking the medication being received at baseline or to switch to a different antipsychotic. First, for patients randomly assigned to treatment with olanzapine (N=314) or risperidone (N=321), the authors assessed the impact of being assigned to stay with the medication they were receiving at entry into the study versus being assigned to switch to these medications from a different antipsychotic. Second, for patients whose baseline antipsychotic was olanzapine (N=319), risperidone (N=271), or quetiapine (N=94), the authors examined the impact of being randomly assigned to stay with the same antipsychotic versus switch. Finally, the authors assessed the impact of removing the data of 209 patients whose random assignment was to stay with their baseline antipsychotic. The authors followed analysis strategies for CATIE; primary outcome was time until all-cause treatment discontinuation. Individuals randomly assigned to olanzapine and ri...Continue Reading

Associated Clinical Trials

Citations

Sep 29, 2007·Advances in Therapy·Edward KimAndrei Pikalov
Jul 16, 2008·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Nov 13, 2009·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Oct 20, 2009·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller, Wolfgang Maier
Jul 27, 2007·Administration and Policy in Mental Health·Nancy H CovellSusan M Essock
Nov 13, 2012·The Psychiatric Quarterly·J C HoblynUNKNOWN CSP 555 Investigator Group
Sep 22, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ion-George AnghelescuMark E Schmidt
May 28, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ofer AgidGary Remington
Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bruce J KinonJohn M Kane
Aug 26, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·John MarchIra D Glick
Oct 10, 2007·Harvard Review of Psychiatry·Theo C Manschreck, Roger A Boshes
Jul 20, 2007·Schizophrenia Bulletin·R A RosenheckMichael Sernyak
Feb 5, 2008·Schizophrenia Bulletin·T Scott Stroup, John R Geddes
Mar 13, 2008·Schizophrenia Bulletin·John M Davis, Stefan Leucht
May 10, 2013·Harvard Review of Psychiatry·David N OsserTheo Manschreck
Jul 17, 2007·Journal of Clinical Psychopharmacology·Sun H KimIra D Glick
Jan 22, 2008·Journal of Clinical Psychopharmacology·Leonardo CorteseRaj Harricharan
May 3, 2008·Psychiatric Services : a Journal of the American Psychiatric Association·Nancy H CovellSusan M Essock
Sep 3, 2009·Psychiatric Services : a Journal of the American Psychiatric Association·Haiden A HuskampRichard G Frank
May 29, 2009·Cost Effectiveness and Resource Allocation : C/E·Douglas E FariesHaya Ascher-Svanum
Jul 2, 2008·BMC Medicine·John M Davis, Stefan Leucht
Oct 7, 2010·The Journal of Clinical Psychiatry·John M Kane, Christoph U Correll
Oct 2, 2007·Southern Medical Journal·Jonathan M Meyer
Nov 28, 2013·Issues in Mental Health Nursing·Colleen CunninghamJudy Mannix
Apr 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·Robert RosenheckJeffrey Lieberman
Jul 1, 2010·Expert Review of Neurotherapeutics·Lawrence Maayan, Christoph U Correll
Apr 10, 2008·Current Medical Research and Opinion·Douglas E FariesBruce J Kinon
Mar 29, 2014·Current Medical Research and Opinion·Leslie CitromeTony Hebden
Nov 30, 2010·General Hospital Psychiatry·Joyce C WestDarrel A Regier
Mar 1, 2010·Asian Journal of Psychiatry·Babu Rankupalli, Rajiv Tandon
May 16, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Chi-Un PaeIn-Ho Paik
Mar 3, 2009·L'Encéphale·A CharpentierP Thomas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2021 Meta ULC. All rights reserved